Sachi Okawa 研究室（岡山大学・Okayama University Hospital）

AI 要約（直近 5 年の研究成果）

本研究室は、遺伝子変異を持つ肺がん、特にEGFR遺伝子変異を有する非小細胞肺がんの治療抵抗性メカニズムと克服戦略の解明に取り組んでいます。これらのがんは腫瘍内で炎症反応が低く、免疫療法の効果が限定的であるという課題を扱っています。分子標的薬による治療後に発生する耐性獲得のメカニズムを、実験室での細胞実験とマウスモデルを用いた生体内実験の両面から調査しており、耐性細胞が生じるしくみを明らかにしようとしています。分子標的薬単独では十分な効果が得られないため、複数の異なる作用メカニズムを持つ薬剤を組み合わせる治療戦略の開発に注力しています。具体的には、標的薬と免疫チェックポイント阻害薬、血管新生阻害薬、または細胞内シグナル伝達経路の阻害薬を組み合わせることで、腫瘍内の免疫環境を改善し、CD8陽性T細胞などの抗腫瘍免疫応答を強化できるかを検討しています。同時に、臨床患者データの収集・解析により、実験室で得た知見と臨床現場での効果を対応させる研究も進めています。これにより、難治性肺がんに対する新たな治療選択肢の創出を目指しています。

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

外部リンク

研究成果（24 件）

[2026] Afatinib Overcomes Osimertinib Resistance via Egfr <scp>V804F</scp> Mutation in a Syngeneic Egfr ‐Mutant Lung Cancer Mouse Model
DOI: https://doi.org/10.1111/cas.70431
[2026] Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve Egfr-Mutant Lung Cancer with Non-Inflamed Tumor Microenvironment
DOI: https://doi.org/10.3390/curroncol33060315
[2026] Successful hemostasis of intractable hemoptysis with endobronchial Watanabe spigots following endoscopic thrombin injection into the bleeding bronchus in an inoperable patient
DOI: https://doi.org/10.1016/j.resinv.2026.101388
[2026] <scp>TGF</scp> ‐β Inhibitor Potentiates Osimertinib‐Induced Anti‐Tumor Immunity in Egfr ‐Mutant Lung Cancer
DOI: https://doi.org/10.1111/cas.70352
[2026] Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr ‐mutated lung cancer
DOI: https://doi.org/10.1002/1878-0261.70264
[2025] Data from Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation
DOI: https://doi.org/10.1158/1535-7163.c.8125941
[2025] Supplementary Figure S1 from Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation
DOI: https://doi.org/10.1158/1535-7163.30516024
[2025] Supplementary Figure S3 from Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation
DOI: https://doi.org/10.1158/1535-7163.30516018
[2025] Supplementary Figure S4 from Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation
DOI: https://doi.org/10.1158/1535-7163.30516015
[2025] Supplementary Figure S2 from Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation
DOI: https://doi.org/10.1158/1535-7163.30516021

続きを表示（残り 14 件）

[2025] Promising Effectiveness of Combined Chemotherapy and Immunotherapy in Patients with Advanced Non-small Cell Lung Cancer: A Real-World Prospective Observational Study (CS-Lung-003).
DOI: https://doi.org/10.18926/amo/68724
[2025] Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation
DOI: https://doi.org/10.1158/1535-7163.mct-25-0002
[2024] P64-3 Why are protocol-related queries in Japan remarkably increased compared to other regions? Survey targeting CRCs and CRAs
DOI: https://doi.org/10.1016/j.annonc.2024.07.443
[2024] Lymphangioleiomyomatosis: Rapidly Progressive Retroperitoneal Cystic Tumor Mimicking Malignancy
DOI: https://doi.org/10.2169/internalmedicine.3254-23
[2024] Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study
DOI: https://doi.org/10.1007/s00432-024-05618-4
[2023] An immunocompetent case of chronic pulmonary aspergillosis caused by Aspergillus viridinutans
DOI: https://doi.org/10.1016/j.resinv.2023.11.008
[2023] CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
DOI: https://doi.org/10.21037/tlcr-23-99
[2023] PD-1 blockade augments CD8+ T cell dependent antitumor immunity triggered by Ad-SGE-REIC in Egfr-mutant lung cancer
DOI: https://doi.org/10.1016/j.lungcan.2023.01.018
[2022] CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr -Mutant Lung Cancer
DOI: https://doi.org/10.1158/2326-6066.cir-21-0751
[2022] Identification of targetable kinases in idiopathic pulmonary fibrosis
DOI: https://doi.org/10.1186/s12931-022-01940-y
[2021] MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I
DOI: https://doi.org/10.1038/s41467-021-25728-8
[2021] Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related Disease
DOI: https://doi.org/10.2169/internalmedicine.6470-20
[2021] A case of interstitial pneumonia associated with systemic sclerosis and primary peritoneal serous carcinoma successfully treated with cyclophosphamide
DOI: https://doi.org/10.1007/s13691-021-00475-1
[2021] VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers
DOI: https://doi.org/10.1111/cas.14801

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。

AI 要約（直近 5 年の研究成果）

外部リンク

関連研究室(8 件)

研究成果（24 件）

科研費（0 件）

所属学会・役職（0 件）